Sequenom, Inc. (NASDAQ:SQNM) announced the Company’s participation at the Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY on June 2-3, 2014. Sequenom, Inc. (NASDAQ:SQNM) net profit margin is -55.10% and weekly performance is 4.51%. On last trading day company shares ended up $3.01. Analysts mean target price for the company is $4.40. Sequenom, Inc. (NASDAQ:SQNM) distance from 50-day simple moving average (SMA50) is 15.15%.
On 21 MAY Northwest Biotherapeutics, Inc (NASDAQ:NWBO) reported ($0.46) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.13, Analyst Ratings Network.com reports. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares advanced 12.01% in last trading session and ended the day on $6.53. NWBO return on assets is -898.30%. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) quarterly performance is -3.55%.
On 20 MAY Arrowhead Research Corp (NASDAQ:ARWR) represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 64%. Arrowhead Research Corp (NASDAQ:ARWR) shares moved up 12.82% in last trading session and was closed at $12.85, while trading in range of $11.47 – $12.94. Arrowhead Research Corp (NASDAQ:ARWR) year to date (YTD) performance is 18.43%.
On 9 MAY Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its results of operations for the quarter ended March 31. First quarter revenue totaled $1.8 million, down from $2.2 million in 2013, reflecting royalty income of $0.7 million compared to $1.2 million in the 2013 period, based on RELISTOR(R) net sales (in millions) reported to Progenics by our commercialization partner Salix. Net sales declined to $4.8 million in the current quarter from prior quarter net sales of $19.0 million. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended the last trading day at $3.94. Company weekly volatility is calculated as 4.94% and price to cash ratio as 4.16. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a positive weekly performance of 4.79%.
PTC Therapeutics, Inc. (NASDAQ:PTCT) saw its shares surge a whopping 30.74% on the day. This tremendous rally can be attributable to solid volume too with far more shares changing hands than in a normal session. PTC Therapeutics, Inc. (NASDAQ:PTCT) weekly performance is 35.42%. On last trading day company shares ended up $21.18. Analysts mean target price for the company is $38.33. PTC Therapeutics, Inc. (NASDAQ:PTCT) distance from 50-day simple moving average (SMA50) is -1.03%.
Leave a Reply